Vogenx (NASDAQ:VOGX) Raised to Strong-Buy at JonesTrading

Vogenx (NASDAQ:VOGX) was upgraded by analysts at JonesTrading to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Separately, Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a research report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Vogenx has an average rating of “Strong Buy” and an average target price of $55.00.

Vogenx Trading Down 2.6%

NASDAQ VOGX opened at $33.13 on Monday. Vogenx has a 52 week low of $12.95 and a 52 week high of $35.50.

Vogenx Company Profile

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.